Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT) by Connor, P. et al.
REGULAR ARTICLE
Safety and efficacy of rivaroxaban in pediatric cerebral venous
thrombosis (EINSTEIN-Jr CVT)
Philip Connor,1,* Mayte Sánchez van Kammen,2,* Anthonie W. A. Lensing,3 Elizabeth Chalmers,4 Krisztián Kállay,5 Kerry Hege,6
Paolo Simioni,7 Tina Biss,8 Fanny Bajolle,9 Damien Bonnet,9 Sebastian Grunt,10 Riten Kumar,11 Olga Lvova,12 Rukhmi Bhat,13
An Van Damme,14 Joseph Palumbo,15 Amparo Santamaria,16 Paola Saracco,17 Jeanette Payne,18 Susan Baird,19 Kamar Godder,20
Veerle Labarque,21 Christoph Male,22 Ida Martinelli,23 Michelle Morales Soto,24 Jayashree Motwani,25 Sanjay Shah,26
Helene L. Hooimeijer,27 Martin H. Prins,28 Dagmar Kubitza,3 William T. Smith,29 Scott D. Berkowitz,29 Akos F. Pap,3 Madhurima Majumder,29
Paul Monagle,30-32 and Jonathan M. Coutinho,2 for the EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators
1The Noah’s Ark Children’s Hospital for Wales, Cardiff, United Kingdom; 2Department of Neurology, Amsterdam University Medical Center (UMC), University of Amsterdam,
Amsterdam, The Netherlands; 3Bayer AG, Wuppertal, Germany; 4Royal Hospital for Children, Glasgow, United Kingdom; 5Department of Pediatric Hematology and Stem Cell
Transplantation, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary; 6Riley Hospital For Children at Indiana
University (IU) Health, Indianapolis, IN; 7Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine (DIMED), Padua University Hospital, Padua, Italy; 8Department of
Haematology, The Newcastle upon Tyne Hospitals, National Health Service (NHS) Foundation Trust, Newcastle upon Tyne, United Kingdom; 9M3C-Necker Enfants Malades,
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lants had a low risk of
recurrent VTE or clini-
cally relevant bleeding.
Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in
randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard
anticoagulants in thepredefinedsubgroupof childrenwith cerebral venous thrombosis (CVT)
who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after
initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued
on heparin or switched to vitamin K antagonist). The main treatment period was 3 months.
The primary efficacy outcome, symptomatic recurrent venous thromboembolism (VTE), and
principal safety outcome, major or clinically relevant nonmajor bleeding,were centrally
evaluated by blinded investigators. Sinus recanalization on repeat brain imaging was
a secondary outcome. Statistical analyses were exploratory. In total, 114 children with
confirmed CVT were randomized. All children completed the follow-up. None of the 73
rivaroxaban recipients and 1 (2.4%; CVT) of the 41 standard anticoagulant recipients had
symptomatic, recurrent VTE after 3 months (absolute difference, 2.4%; 95% confidence
interval [CI],22.6% to 13.5%). Clinically relevant bleeding occurred in 5 (6.8%; all nonmajor
and noncerebral) rivaroxaban recipients and in 1 (2.5%; major [subdural] bleeding)
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standard anticoagulant recipient (absolute difference, 4.4%; 95% CI, 26.7% to 13.4%).
Complete or partial sinus recanalization occurred in 18 (25%) and 39 (53%) rivaroxaban
recipients and in 6 (15%) and 24 (59%) standard anticoagulant recipients, respectively. In
summary, in this substudy of a randomized trial with a limited sample size, children with
CVT treated with rivaroxaban or standard anticoagulation had a low risk of recurrent VTE
and clinically relevant bleeding. This trial was registered at clinicaltrials.gov as
#NCT02234843.
Introduction
Cerebral venous thrombosis (CVT) is a rare type of stroke in
childhood with an estimated incidence of 0.7 per 100000 children
per year.1 CVT typically causes severe headache and may result in
vision problems, seizures, focal neurologic deficits, decreased level
of consciousness, and death.2-4 Commonly reported risk factors for
pediatric CVT include birth complications, infection of the head or
neck, cancer, traumatic head injury, acquired or inherited thrombo-
philia, and use of hormonal contraceptive methods.1,3-7
In adults with CVT, therapeutic anticoagulation is widely consid-
ered the mainstay of treatment,8,9 although only supported by
data from a few small, randomized trials,10-12 which included
only a few patients with infectious CVT. A unique challenge of
anticoagulation in CVT compared with other types of venous
thromboembolism (VTE) is the high proportion of patients who
are at risk for development of intracranial hemorrhage. In children
with CVT (ie, neonates and older children), use of anticoagu-
lant therapy, with the potential for intracranial hemorrhage,
is more controversial because of the absence of clinical trials
and the infectious nature of CVT in many children.13-16 However,
the potential short-term risk of withholding anticoagulants
is extension of the thrombus with associated neurological
deterioration.17,18
Recently, the direct factor Xa inhibitor rivaroxaban was compared
with standard anticoagulation for the treatment of acute VTE of all
types in 500 children of all ages (EINSTEIN-Jr).19,20 The body
weight–adjusted oral rivaroxaban treatment regimens successfully
targeted the adult rivaroxaban exposure range without the need for
laboratory monitoring.20-22 Recurrent VTE occurred infrequently
with both rivaroxaban and standard anticoagulation, and no major
bleeding events were observed with rivaroxaban.19 The absolute
incidences of study outcomes and relative treatment effects
observed with rivaroxaban were similar to those in the large
rivaroxaban VTE studies in adults.19,23-25
We present a predefined subgroup analysis of the safety and
efficacy of rivaroxaban and standard anticoagulants in the 114
children who presented with CVT in the EINSTEIN-Jr phase 3 trial.19
Methods
Study design and patients
This is a substudy of the EINSTEIN-Jr phase 3 trial, which was
a multicenter, open-label, randomized trial that compared
the efficacy and safety of rivaroxaban with those of standard
anticoagulants for the treatment of pediatric VTE. The study
protocol, the clinical efficacy and safety results, and the
rivaroxaban dose-exposure response have been published.19,20,25
The statistical analysis plan for this prespecified substudy can be
found in the supplemental Data. The institutional review board
at each participating center approved the study protocol. Written
permission from a parent or guardian and, when appropriate, the
child’s assent, were obtained. An independent data-monitoring
committee periodically reviewed the study outcomes. The substudy
was conducted at 51 sites in 20 countries (Australia, Turkey,
Israel, and China and other countries in Europe, South
America, and North America). The main study treatment period
was 3 months.
CVT was defined as thrombosis of any of the cerebral veins or
sinuses diagnosed by computed tomography (CT)–venography,
or magnetic resonance imaging (MRI) with magnetic resonance
venography. Children with isolated jugular vein thrombosis did
not qualify for this subgroup. Children with CVT were consid-
ered if treatment had been initiated with unfractionated heparin,
low-molecular-weight heparin, or fondaparinux. Children youn-
ger than 0.5 year were required to have a gestational age at
birth of at least 37 weeks and body weight above 2600 g and
to have received oral feeding for at least 10 days. The main
exclusion criteria were active bleeding or a high risk of bleed-
ing that contraindicated anticoagulant therapy; an estimated
glomerular filtration rate ,30 mL/min per 1.73 m2; or, if aged
,1 year, serum creatinine .97.5th percentile. CVT-associated
intracerebral hemorrhage was not an exclusion criterion.
The full list of eligibility criteria is provided in supplemental
Table 1.
Enrollment started with children aged 12 to 17 years followed by
those aged 6 to 11 and 2 to 5 years and 0.5 to 1 and,0.5 year, as
described previously.19
Randomization and study medication
After completion of 5 to 9 days of anticoagulation with unfractio-
nated heparin, low-molecular-weight heparin, or fondaparinux, the
children were randomized, by using an interactive Web response
system and permuted blocks of 3, in a 2:1 ratio to receive either
open-label rivaroxaban or standard anticoagulation. Randomization
was stratified per age group and site of VTE (extremity venous
thrombosis, pulmonary embolism, caval or catheter-related throm-
bosis vs CVT or jugular, renal, or portal vein thrombosis). Children in
the standard anticoagulation group continued with heparin
treatment or were switched to a vitamin K antagonist, at the
discretion of the treating physician, at therapeutic doses, accord-
ing to international guidelines.13-15 Children allocated to rivarox-
aban received a body weight–adjusted 20-mg equivalent dose,
given 1, 2, or 3 times daily for body weights of$30, 12 to,30, and
,12 kg, respectively (supplemental Table 2). Rivaroxaban was
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administered as immediate-release, film-coated tablets available in
strengths of 5, 10, 15, or 20 mg, or as a newly developed
suspension for oral use.20
Follow-up and outcomes
All children who stopped study treatment earlier than scheduled
were observed until the end of the 3-month treatment period.
Patients and their parents were instructed to report to the study
center if the patients had symptoms suggestive of recurrent
thrombosis or bleeding. The primary efficacy outcome was
symptomatic recurrent VTE (extremity deep venous thrombosis;
pulmonary embolism; CVT; or jugular, caval, renal, portal vein, or
catheter-related thrombosis). The principal safety outcome was the
composite of overt major and clinically relevant nonmajor bleeding,
according to the criteria defined by the International Society of
Thrombosis and Haemostasis (supplemental Table 3).26,27 Repeat
imaging of the cerebral venous system was performed at the end
of the study treatment period and compared with baseline images.
The degree of cerebral vein and sinus recanalization was classified
as normalized (ie, no residual thrombus observed), improved (ie,
thrombus still present, but partly recanalized or involving fewer
venous segments), no relevant change (ie, not recanalized and
similar in extent), or deteriorated (ie, new venous segment involved).
The degree of recanalization was classified as uncertain if repeat
imaging was not performed or not evaluable, or if repeat imaging
was performed ,7 days before or .7 days after cessation of the
study medication. In addition, the baseline and repeat imaging
tests were evaluated to describe the extent and anatomical
location of the CVT and to assess the presence of focal edema
or intracerebral hemorrhage. Intracerebral hemorrhage was
defined as either intraparenchymal hemorrhage or hemorrhagic
infarction. Secondary outcome measures were a composite
of symptomatic recurrent VTE and asymptomatic deterioration
on repeat imaging and a composite of symptomatic recurrent
VTE and major bleeding. A blinded, independent adjudication
committee of experienced neurologists and thrombosis experts
(study committees are listed in the supplemental Data) evaluated
the initial diagnosis, suspected primary and secondary out-
comes, and all repeat imaging. Two experienced neurologists
from the adjudication committee independently assessed the
baseline and repeat imaging, and disagreements were resolved
by a third reviewer. In addition, the adjudication committee
classified the individual risk factor profile for VTE as unpro-
voked or provoked by a permanent or transient risk factor.
Thrombophilia screening was performed locally at the discre-
tion of the local treating physician. Details on the total number
of children screened for thrombophilia and method of throm-
bophilia screening were not routinely collected. Local inves-
tigators classified the CVT as symptomatic or asymptomatic
and recorded the occurrence of headache or seizures during
the study period, as well as the presence of focal neurologic
deficits, visual disturbances, and increased requirement of help
with activities of daily living (ADL) at 3 months vs before
the CVT.
Statistical analysis
The EINSTEIN-Jr trial and, consequently, this substudy were
not powered for confirmatory analyses, because the incidence
of venous thrombosis in children is ;100 times lower than in
adults, which renders well-powered studies unfeasible.19 Efficacy
outcomes were considered during the 3-month study treat-
ment period (intention to treat), whereas safety outcomes were
considered for the same period but only during the time from
administration of the first dose of study medication to 48 hours
after the administration of the last dose. For comparison of
the ordered categories of change in thrombotic burden (ie,
normalized, improved, uncertain, no relevant change, asymptom-
atic deterioration, or symptomatic recurrent VTE), the Wilcoxon
rank-sum test was used. Confidence intervals (CIs) for inciden-
ces and for absolute risk differences were calculated by exact
methods. Calculations were performed by M.M. using SAS v9.2
(SAS Institute Inc., Cary, NC) and StatXact (r) PROCs (v10.0)
(Cytel Inc, Cambridge, MA).
Results
From 2 March 2015 through 26 November 2018, 117 children with
CVT were randomized (Figure 1). In 3 children, the presence of CVT
was not confirmed after randomization. Demographics, clinical, and
radiological characteristics of the remaining 114 children (rivarox-
aban, 73; standard anticoagulation, 41) are shown in Table 1. The
most common presenting symptoms were headache (n 5 81;
71%), focal neurological deficits (n 5 34; 30%), diplopia (n 5 22;
19%), and seizures (n 5 12; 11%), and 4 (3.5%) children were in
a coma. Baseline head CT or MRI scan revealed focal edema,
intracerebral hemorrhage, or both in 12 (11%), 6 (5.3%), and 4
(3.5%) children, respectively. CVT limited to a single sinus was
found in 32 (28%) children. None of the children had isolated
cortical vein thrombosis. Overall, CVT was unprovoked in 5 (4.4%)
children and was provoked by transient or permanent risk factors in
84 (74%) and 25 (22%) children, respectively (Table 2). Infectious
disease was observed in 76 (67%) children, of whom 74 (97%) had
a local infection of the head or neck. Active cancer and (acquired
or inherited) thrombophilia occurred in 9 (7.9%) and 8 (7.0%)
children, respectively.
All children received initial anticoagulant therapy with low-molecu-
lar-weight heparin (n5 106, 93%) or unfractionated heparin (n5 8,
7.0%). Two children (1.8%) received thrombolytic therapy. All 41
children allocated to standard anticoagulation treatment continued
with low-molecular-weight heparin, of whom 6 (15%) transitioned to
vitamin K antagonist therapy. Following completion of the 3-month
study duration, 53 (46%) of the 114 children continued anticoag-
ulant therapy. The median study treatment duration was 92 days
with an interquartile range of 87 to 95 and 90 to 95 days for
rivaroxaban and standard anticoagulation, respectively. All children
completed the follow-up.
Efficacy
Symptomatic recurrent VTE occurred in none of the 73 children
in the rivaroxaban group (95% CI, 0.0-4.9) and in 1 of the 41
children in the standard anticoagulation group (recurrent CVT,
2.4%; 95% CI, 0.1-12.4), for an absolute risk difference in favor
of rivaroxaban of 2.4% (95% CI 22.6% to 13.5%; Table 3). The
composite of recurrent VTE and asymptomatic deterioration on
repeat imaging was found in none of the rivaroxaban recipients
and in 2 (4.9%) of the standard anticoagulation recipients
(absolute risk difference in favor of rivaroxaban, 4.9%; 95% CI
20.4% to 17.1%). Overall, repeat imaging demonstrated a similar
effect on clot resolution with rivaroxaban as compared with
standard anticoagulation (Table 4; Wilcoxon rank-sum test,
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P 5 .20). Complete recanalization of the index thrombosis
occurred in 18 children (25%) in the rivaroxaban group, as
compared with 6 children (15%) in the standard anticoagulation
group (unadjusted odds ratio [OR], 1.63; 95% CI, 0.78-3.41).
Incomplete recanalization occurred in a further 39 (53%) and 24
(59%) children, respectively, whereas asymptomatic deteriora-
tion of the CVT was found in a single child (2.4%) in the standard
anticoagulation group.
Safety
Clinically relevant bleeding was observed in 5 of the 73
rivaroxaban recipients (6.8%; all were nonmajor extracranial
bleeding events) and in 1 of the 41 standard anticoagulation
recipients (2.4%; major [subdural] bleeding event), for an
absolute risk difference in favor of standard anticoagulation of
4.4% (95% CI, 26.7% to 13.4%; Table 3). The composite of
recurrent VTE or major bleeding occurred in none of the 73
children in the rivaroxaban group and in 2 of the 41 children
(4.9%) in the standard anticoagulation group (absolute risk
difference in favor of rivaroxaban, 4.9%; 95% CI, 20.4% to
17.1%).
Clinical course during the 3-month treatment period
During the 3-month treatment period, headache lasting for more
than 2 weeks occurred in 6 (8.2%) of the rivaroxaban recipients and
in 2 (4.9%) of the standard anticoagulation recipients (Table 4).
Epileptic seizures occurred in 1 (1.4%) child in the rivaroxaban
group.
At the end of the 3-month study treatment period, none of the
children had died. Focal neurologic deficits were still present
in 5 (6.8%) and 3 (7.3%) children in the rivaroxaban and
standard anticoagulation group, respectively (Table 4). Thus,
baseline focal neurologic deficits had resolved in 20 (27%)
children in the rivaroxaban group and in 6 (15%) children in
the standard anticoagulant group (Tables 1 and 4). Four
(5.5%) rivaroxaban recipients and 3 (7.3%) standard anti-
coagulation recipients required more help with ADL than
before the CVT. None of the children had a new intracerebral
hemorrhage or nonhemorrhagic infarct. No important differ-
ences were found between children who presented with
symptomatic CVT and those who had asymptomatic CVT
(supplemental Table 4).
Discussion
In children with CVT treated with initial heparin followed by 3 months
of treatment with either rivaroxaban or standard anticoagula-
tion, we observed low rates of symptomatic recurrent throm-
bosis and major bleeding, no new nonhemorrhagic infarcts
or intracerebral hemorrhages, high rates of complete or partial
520 children were screened for
eligibility for the EINSTEIN Jr
phase 3 trial
20 did not meet eligibility criteria
500 children enrolled in the
EINSTEIN Jr phase 3 trial
335 were assigned to receive
rivaroxaban
165 were assigned to receive
standard anticoagulation
73 diagnosed with cerebral venous
thrombosis
44 diagnosed with cerebral venous
thrombosis
3 had diagnosis revised*
1 had arterial stroke
1 had ophthalmic vein thrombosis
1 had no abnormalities
41 included in current substudy
             All received allocated study medication
             1 discontinued study medication due to
             adverse event
             All had complete follow-up
73 included in current substudy
             All received allocated study medication
             None discontinued study medication 
             due to adverse event
             All had complete follow-up
Figure 1. Flowchart of selection of patients for
the EINSTEIN-Jr CVT substudy. *Withdrew from the
study before any of the outcomes had occurred.
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sinus recanalization, and good clinical outcome in most children.
CVT was associated with transient or permanent risk factors
for VTE in .95% of the children, with head and neck infection
being the main risk factor in almost two-thirds of them. Our
study represents, to our knowledge, the first prospective trial of
anticoagulation in pediatric CVT and further substantiates the
efficacy and safety of anticoagulant therapy in pediatric CVT.
The current suggestion for the use of anticoagulant therapy in
pediatric CVT is based on results from small randomized trials
in adult CVT,10-12 cohort studies of pediatric CVT,1,17,28,29 as
well as pathophysiological plausibility.13-15 In the pediatric
cohort studies, anticoagulant treatment was associated with
a reduced risk of severe neurologic deficit or death at hospital
discharge (OR, 0.32; 95% CI, 0.14-0.73),29 reduced mortality
(1.8% vs 10%),15 lower risk of recurrent VTE (3.6% vs 7.3%







Male sex 46 (63) 23 (56)
Age groups
Birth to 1 y 4 (5.5) 5 (12)
2-5 y 22 (30) 12 (29)
6-11 y 31 (42) 15 (37)
12-17 y 16 (22) 9 (22)
Clinical presentation, n (%)
Headache 51 (70) 30 (73)
Focal neurological deficits* 25 (34) 9 (22)
Epileptic seizure 6 (8.2) 6 (15)
Papilledema 23 (32) 11 (27)
Diplopia 15 (21) 7 (17)
Decreased vision 8 (11) 2 (4.9)
Coma† 3 (4.1) 1 (2.4)
Asymptomatic presentation CVT 11 (15) 7 (17)
CT-/MR-venography, n (%)
Parenchymal lesions
Focal edema 9 (12) 7 (17)
Intracerebral hemorrhage 7 (10) 3 (7.3)
Thrombosis location(s)
Superior sagittal sinus 13 (18) 8 (19.5)
Lateral sinus‡ 63 (86) 35 (85)
Straight sinus 7 (9.6) 4 (9.8)
Deep venous system 5 (6.8) 3 (7.3)
Cortical veins 7 (9.6) 2 (4.9)
Cavernous sinus 4 (5.5) 3 (7.3)
Jugular vein 39 (53) 19 (46)
Rivaroxaban group, n (%)§
Tablet 19 (26) NA
Suspension 54 (74) NA
Standard anticoagulation group, n (%)§
LMWH NA 35 (85)
LMWH followed by vitamin K
antagonists
NA 6 (15)
Study treatment duration, median (IQR),
d
92 (87-95) 92 (90-95)
IQR interquartile range; LMWH, low-molecular-weight heparin; NA, not applicable.
*Motor weakness, aphasia, sensory deficits, hemianopia.
†Coma was defined as a Glasgow Coma Scale score of ,9.
‡Composite of the sigmoid and transverse sinuses.
§One child in each treatment arm also received thrombolytic therapy, both
uncomplicated.





Etiology of index CVT, n (%)
Transient risk factor only 50 (69) 34 (83)
Persistent risk factor* 21 (29) 4 (9.8)
Unprovoked 2 (2.7) 3 (7.3)
Type of risk factor, n (%)†
Infectious disease 46 (63) 30 (73)
Otitis media and/or mastoiditis‡ 39 (53) 20 (49)
CNS infection‡ 12 (16) 9 (22)
Sinusitis‡ 12 (16) 6 (15)
Infection other than head or neck 1 (1.4) 1 (2.4)
Major head trauma 5 (6.8) 3 (7.3)
Major surgery§ 4 (5.5) 1 (2.3)
Use of estrogens or progestins 3 (60) || 2 (50) ||
Active cancer{ 7 (9.6) 2 (4.9)
Hematologic cancer# 5 (6.8) 2 (4.9)
Solid tumor** 2 (2.7) 0
Renal inflammatory disease†† 5 (6.8) 0
Cerebral arteriovenous malformation 1 (1.4) 1 (2.4)
Known inherited thrombophilia 5 (6.8) 0
Antithrombin, protein C, or S
deficiency
3 (4.1) 0
Factor V Leiden or prothrombin
mutation
2 (2.7) 0
Acquired thrombophilia‡‡ 2 (2.7) 1 (2.4)
Familial venous thrombosisa 1 (1.4) 0
*With or without transient risk factor(s).
†CVT was not related to the use of central venous catheters, hyperthyroidism, dural
arteriovenous fistula, or paroxysmal nocturnal hemoglobinuria.
‡The subcategories of head or neck infections overlap substantially; 41 of 74 (55%)
children with a head or neck infection underwent a surgical intervention (26 of 45 [58%] in
the rivaroxaban group and 15 of 29 [52%] in the standard anticoagulant group).
§Mastoidectomy (n 5 4) and medulloblastoma (n 5 1).
||Percentages calculated for girls aged 12 to 17 years in the rivaroxaban group (n 5 5)
and in the standard anticoagulation group (n 5 4).
{Active cancer is defined as presence of metastases or cancer recently (,6 months)
diagnosed or treated.
#Acute lymphoblastic leukemia (n 5 5) and non-Hodgkin lymphoma (n 5 2).
**Medulloblastoma and rhabdomyosarcoma.
††Nephrotic syndrome (n 5 4) and lupus nephritis (n 5 1).
‡‡Antiphospholipid syndrome (lupus anticoagulant, anti-cardiolipin, and/or anti-b2-
glycoprotein antibodies); none of the children were triple positive for antiphospholipid
antibodies.
aFirst degree (parent or sibling).
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at a median treatment duration of 6 months),17 and lower rates
of thrombus propagation on repeat imaging within 2 weeks
(6.0% vs 32%),28 whereas intracranial bleeding rates with
anticoagulant treatment varied from 0% to 6%.1,28 Thus, the
observed frequencies of these outcomes in both arms of
our study compare well with the reported frequencies among
children treated with anticoagulants in the cited cohort
studies.
Only a few adults presented with septic CVT in the previous
randomized trials,10-12 and some physicians have voiced concerns
about a possible increased risk of intracerebral hemorrhage
in this patient group.16 In an observational study on adult CVT,
57 of the 624 (9.1%) patients had an associated head or neck
infection.30 Those with head or neck infection had an increased
risk of new intracerebral hemorrhages (12.3%) than did those
without a local infection (5.3%). The use of therapeutic anti-
coagulation with heparin did not seem to influence the risk of
new intracranial hemorrhages, but the number of patients who
did not receive anticoagulation was too small to draw firm
conclusions. In our pediatric study, 74 of the 114 (65%)
children had CVT associated with head or neck infections, and
none of those children (all of whom received therapeutic
anticoagulation) developed an intracerebral hemorrhage. A
single child with infectious CVT in the standard anticoagulation
group had a subdural hematoma while receiving the study
medication. Thus, although the absolute group sizes of adults
(n 5 47) and children (n 5 74) with CVT and a head or neck
infection who received anticoagulant treatment were compa-
rable, a minimum of 6 (12.8%) of the adults compared with
none of the children developed an intracerebral hemorrhage
during anticoagulant treatment, providing important safety in-
formation on the use of anticoagulant treatment of this patient
group.
Strengths of our study include the randomized, multicenter design;
the central blinded end point evaluation; and the absence of loss
to follow-up. Randomization occurred early, within 5 to 9 days
after diagnosis of CVT. Moreover, the 2:1 randomization ratio led
to more precise estimates of outcomes in the rivaroxaban group.
In addition, standard anticoagulation was administered according
to current guidelines.13-15
Several limitations also warrant comment. First, although it was
predefined, the current study was a subgroup analysis and was
not powered for hypothesis testing. Therefore, we refrained from
formal statistical comparisons between rivaroxaban and standard
Table 3. Prespecified efficacy and safety outcomes
Rivaroxaban (n 5 73) Standard anticoagulation (n 5 41) Absolute difference (95% CI)
Efficacy population, n (%)
Symptomatic recurrent VTE 0 1 (2.4)* 2.4% (22.6% to 13.5%)
Symptomatic recurrent VTE or asymptomatic deterioration on
repeat imaging
0 2 (4.9) 4.9% (20.4% to 17.1%)
Symptomatic recurrent VTE or major bleeding 0 2 (4.9) 4.9% (20.4% to 17.1%)
Safety population, n (%)
Major or clinically relevant nonmajor bleeding 5 (6.8) 1 (2.4) 4.4% (26.7% to 13.4%)
Major bleeding 0 1 (2.4)†
Clinically relevant nonmajor bleeding 5 (6.8)‡ 0
*Recurrent CVT; occurred in a 6-year-old child with otitis media during the index event. No thrombophilia was reported.
†Subdural hematoma; occurred in a 6-month-old child with bacterial meningitis during the index event.
‡One case each of Mallory-Weiss bleeding in a 15-year-old child with lymphoma, hemorrhoidal bleeding in a 14-year-old child with factor VII deficiency and homocystinuria, and hematuria
in a 10-year-old child with lupus nephritis; 2 cases of nasal bleeding (1 in a 4-year-old child with otitis media during the index event and 1 in an 8-year-old child with nephrotic syndrome).






Clinical course, n (%)
During the 3-mo treatment period
Headache lasting .2 wk* 6 (8.2) 2 (4.9)





5 (6.8) 3 (7.3)
Persisting decreased vision 4 (5.5) 1 (2.4)
Inability to walk/move as before the
CVT
1 (1.4)‡ 0
Requirement of more help with ADL
than before the CVT
4 (5.5)§ 3 (7.3)
Results of repeat imaging at 3 mo, n (%)
New nonhemorrhagic infarct or
intracerebral hemorrhage
0 0
Change in thrombotic burden as compared with index event
Normalized 18 (25) 6 (15)
Improved 39 (53) 24 (59)
No relevant change 5 (6.8) 4 (9.8)
Asymptomatic deterioration 0 1 (2.4)
Uncertain|| 11 (15) 5 (12)
*Headache that interfered with normal daily activities.
†Motor weakness, aphasia, sensory deficits, hemianopia.
‡Advanced cancer.
§Advanced cancer in 2 children.
||Repeat imaging not performed, not evaluable, or performed ,7 days before or .7 days
after cessation of study medication.
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anticoagulation. Second, the EINSTEIN-Jr study was an open-
label trial, because of the practical and ethical difficulties of
administering long-term placebo injections and taking blood
samples for sham therapeutic monitoring in children. However,
efficacy, safety, and imaging outcomes were evaluated by
a blinded adjudication committee, and standardized predefined
criteria were used. Third, for ethical reasons, term neonates
and infants were included only after demonstration of the
absence of safety issues with rivaroxaban in older children.
Hence, the number of neonates and infants we included is
relatively low. Neonates with CVT have different risk factors
and comorbidities than older children with CVT, and their
outcome is significantly worse.6,28 Therefore, the results of the
present study can only be applied to a limited extent to term
neonates and infants. Fourth, our cohort may represent a less
ill population than those included in the previous pediatric
cohort studies.3,17,28 In our study, all children were required to
have started therapeutic heparinization, whereas the pediatric
cohort studies included not only those who received anticoagulation
but also those in whom anticoagulation was thought not to be
indicated or contraindicated. It is possible that individual study
physicians chose to exclude children with severe manifesta-
tions of CVT because of a perceived contraindication for
anticoagulation.13,14 In addition, 18 children with asymptom-
atic CVT (as assessed locally) were included in our study. However,
no important differences were found between children who
presented with symptomatic CVT and those who had asymp-
tomatic CVT with regard to rates of symptomatic recurrent
VTE, major bleeding, sinus recanalization on repeat imaging
after 3 months, and increased need for assistance with ADL after
3 months (supplemental Table 4). Finally, our study evaluated
anticoagulant therapy for a period of 3 months, whereas extended
treatment durations are often given in CVT. Indeed, almost half of
the 114 children continued anticoagulant therapy after the main
study treatment period. The optimal duration of anticoagulant
treatment of CVT has thus far not been established in dedicated
clinical trials and, therefore, the decision to stop anticoagulants at
3 months or to extend treatment thereafter should be based on an
individual assessment weighing the perceived long-term risk of
recurrence against the risk of bleeding.
What are the clinical implications of our study? The low point
estimate of recurrent thrombosis and intracranial bleeding in the
rivaroxaban group excludes with 97.5% confidence an incidence
higher than 4.9%, suggesting that in children with CVT in whom
therapeutic anticoagulation is considered necessary, rivaroxaban
may be a good treatment option. Moreover, whereas standard
anticoagulation requires either parenteral administration or frequent
venipunctures for laboratory monitoring, rivaroxaban can be admin-
istered orally, even in the youngest patients, and does not require
routine laboratory monitoring. Indeed, in the current study, 85% of
children in the standard anticoagulation group received long-term,
twice-daily parenteral low-molecular-weight heparin, given that the
alternative standard of care of using vitamin K antagonists is usually
very problematic in young children.
In summary, most children with acute CVT had favorable clinical
outcomes. Both rivaroxaban and standard anticoagulants were
associated with low risks of recurrent thrombosis and major
bleeding.
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3. Ichord RN, Benedict SL, Chan AK, Kirkham FJ, Nowak-Göttl U; International Paediatric Stroke Study Group. Paediatric cerebral sinovenous thrombosis:
findings of the International Paediatric Stroke Study. Arch Dis Child. 2015;100(2):174-179.
4. Heller C, Heinecke A, Junker R, et al; Childhood Stroke Study Group. Cerebral venous thrombosis in children: a multifactorial origin. Circulation. 2003;
108(11):1362-1367.
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